Discover our dynamic leadership team at Actorius Innovations. Join our leadership team to drive innovation and growth today! Our Dynamic Leadership Team Meet the team and learn about our mission. Dr. Jayant Khandare Cofounder, MD & CSO LinkedIn Aravindan Vasudevan Cofounder & Director LinkedIn Rick Kamble Cofounder & Director LinkedIn Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Actorius Innovations and Research Pvt. Ltd. We are a in pursuit of identifying and developing life-saving solutions for global healthcare problems with a focus on cancer diagnostics and cure. Open Positions Job Openings Current openings at Actorius Innovations and Research Research Scientist Department: Research & Development Experience: 3–5 years Location: Pune, India Read More Accounts Manager Department: Finance & Accounts Experience: 5–10 years Location: Pune, India Read More Logistics Manager Department: Logistics & Operations Experience: 5–7 years Location: Pune, India Read More Product Manager Department: Product & Marketing Experience: 3-5 years Location: Mumbai, India Read More Digital Marketing Manager Department: Product & Marketing Experience: 3-5 years Location: Mumbai, India Read More Marketing Manager Department: Product & Marketing Experience: 3–5 years Location: Mumbai, India Read More Regional Sales Manager (RSM) Department: Sales Experience: 10-15 years Location: Assigned Region Read More Zonal Sales Manager (ZSM) Department: Sales Experience: 15-20 years Location: Assigned Zone Read More National Sales Manager (NSM) Department: Sales Experience: 15-20 years Location: Pan India Read More First Prev 1 Page 1 Next Last

Explore the latest resources from Actorius, a leading Oncology focused biotech company. Discover cutting-edge insights and innovations today! Resources Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. Patents Publications Events Press Release Expert Insights 7 Nov 2026 ISLB Annual Congress 2026 | 7-9 November | Madrid, Spain Actorius will present seven scientific posters at ISLB 2026 in Madrid, showcasing research advancing the clinical potential of CTCs across treatment monitoring, biomarker analysis, residual disease, and metastasis research. Read More 13 Sept 2026 Reflections from FHNO 2026 | Kashmir Reflections from FHNO 2026 in Kashmir, where Dr. Jayant Khandare engaged with leading Indian oncologists to exchange perspectives on cancer research, innovation, and the future of oncology. Read More 1 Sept 2026 Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease. Read More 30 Aug 2026 Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling. Read More 30 Aug 2026 Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication. Read More 30 Aug 2026 Algorithm based analysis of circulating tumour cells in cancer patients A study evaluating CellMatrics, a Python-based automated image analysis algorithm for CTC detection, demonstrated rapid and robust concordance with manual CTC analysis across blood samples from 32 cancer patients. Read More 30 Aug 2026 Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients This study evaluated AR-V7 in CTCs and clusters from prostate cancer patients, highlighting its potential to predict ARSI resistance and support dynamic treatment decisions. Read More 30 Aug 2026 Capture of Cancerous Cells and Overall Survival in Rats using Ex-vivo Extracorporeal Device in Multiple Onco-dialysis Cycles An animal study evaluated OncoMetastat for ex-vivo cancer cell capture, safety, and survival in rats. Across multiple onco-dialysis cycles, cancer cells were captured, all test-group rats survived 14 days, and histopathology showed normal tissues. Read More 30 Aug 2026 Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-Cadherin System A study demonstrating N-Cadherin affinity-based capture of EMT-associated CTCs in diverse cancers, with Vimentin-positive CTC detection in 90% of samples and N-Cadherin expression revealing heterogeneous metastatic phenotypes. Read More 30 Aug 2026 Evaluation of circulating tumor cells expressing PD-L1 and CTC clusters at baseline and follow ups in triple-negative breast cancer A retrospective study of 180 TNBC blood samples evaluated CTC burden, PD-L1 expression and CTC clusters using the CDSCO-approved OncoDiscover platform, highlighting their potential for longitudinal disease monitoring and biomarker-guided management. Read More 29 Aug 2026 'कॅन्सर'ची टेस्ट शोधणाऱ्या मराठी माणसाचं आकाशाएवढं कर्तृत्व बघाच ! | डॉ.जयंत खंदारे. धाराशिवच्या डॉ. जयंत खंदारे यांनी अमेरिकेत संशोधन करून रक्तावरून कॅन्सरचे निदान करणारी जगातील केवळ दुसरी टेस्ट विकसित केली आहे. पुणे आणि अमेरिकेत त्यांच्या लॅब असून, कॅन्सर जनजागृतीसह त्यांच्या या महत्त्वपूर्ण शोधाच्या प्रेरणादायी प्रवासाचा घेतलेला हा वेध. Read More 18 Aug 2026 14 Years of Actorius: A Journey of Innovation & Impact From circulating tumor cells and liquid biopsy to better cancer diagnostics —a journey driven by innovation, persistence, and the belief that better diagnostics can change lives. Read More 24 May 2026 The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. Read More 23 Apr 2026 AACR 2026 Highlights | April 17-22 | San Diego, California Highlights from AACR 2026 Read More 17 Mar 2026 ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 Mar 2026 ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 Mar 2026 ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 Mar 2026 AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 Mar 2026 ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 Mar 2026 AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 17 Mar 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 14 Mar 2026 डॉ. जयंत खंदारे के नेतृत्व में एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड करेगी कैंसर की पहचान और मेटास्टेसिस नियंत्रण में नई क्रांतिकारी पहल एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड, एक अग्रणी भारत-अमेरिकी जैव-प्रौद्योगिकी कंपनी है जो आधुनिक सर्कुलेटिंग टयूमर सेल्स (CTC) तकनीकों के माध्यम से ऑन्कोलॉजी के क्षेत्र में परिवर्तन ला रही है। कंपनी के संस्थापक, प्रबंध निदेशक और मुख्य वैज्ञानिक अधिकारी डॉ. जयंत खंदारे के दूरदर्शी नेतृत्व में कंपनी यह उल्लेखनीय प्रगति कर रही है। Read More 14 Mar 2026 Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More 7 Mar 2026 AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 20 Feb 2026 Meeting with our International KOLs Our team meeting with oncology KOLs from the US and Europe. Read More 5 Feb 2026 Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More 27 Jan 2026 Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 3 Nov 2025 PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients This study demonstrates a high prevalence of CTCs in the endometrial cancer population. The presence of CTCs, CTC clusters, and PD-L1–overexpressing CTCs indicates occult minimal residual disease, disease aggressiveness, and potential progression toward metastasis. Read More 3 Nov 2025 Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 Nov 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More First Prev 1 Page 1 Next Last

Actorius Innovations and Research delivers regulatory-aligned cancer research solutions, enabling early detection, accurate monitoring, and impactful clinical decision support. Early is Everything. From breakthrough research to clinically meaningful diagnostics, Actorius is advancing innovations like OncoDiscover® that provide meaningful biological insights, helping clinicians make informed decisions and supporting patients throughout their cancer journey. Know More OncoDiscover® The OncoDiscover® portfolio integrates CTC testing, NGS tumour profiling, and TDM for comprehensive cancer characterisation and longitudinal monitoring. Book a test now Meet us at ISLB 2026 | November 7-9, 2026 | Madrid, Spain About We are in pursuit of identifying and developing life-saving solutions for global healthcare problems with a focus on cancer diagnostics and cure. Trusted by: Why choose us? Our approach is grounded in rigorous research, advanced platforms, and a commitment to meaningful outcomes. 15000+ Patients Served 500+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Accreditations/ Patents CDSCO Approved Test MD - 9; License No. MFG/IVD/2019/000031 NABL Accredited Lab Certificate No. NABLM0726MH08160 ISO Certified Lab ISO 13485:2016 by INTERTEK; Certificate No. 0140783 Globally Patented International Application No. PCT/IB2016/050779 Our Publications In collaboration with researchers and thought leaders around the world, Actorius Innovations' Team combines scientific expertise with cutting-edge innovation to advance the frontiers of cancer care. The research behind our products are supported by 100+ scientific publications presented at leading global forums such as ASCO, AACR, ESMO, ISLB, etc Read our publications Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. View all updates 1 Sept 2026 Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease. Know More 30 Aug 2026 Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling. Know More 30 Aug 2026 Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication. Know More Actorius in Action Stay updated with our latest events, scientific discussions, collaborations, and milestones that continue to shape the future of cancer research and innovation. View all events 7 Nov 2026 ISLB Annual Congress 2026 | 7-9 November | Madrid, Spain Actorius will present seven scientific posters at ISLB 2026 in Madrid, showcasing research advancing the clinical potential of CTCs across treatment monitoring, biomarker analysis, residual disease, and metastasis research. Read More 13 Sept 2026 Reflections from FHNO 2026 | Kashmir Reflections from FHNO 2026 in Kashmir, where Dr. Jayant Khandare engaged with leading Indian oncologists to exchange perspectives on cancer research, innovation, and the future of oncology. Read More 18 Aug 2026 14 Years of Actorius: A Journey of Innovation & Impact From circulating tumor cells and liquid biopsy to better cancer diagnostics —a journey driven by innovation, persistence, and the belief that better diagnostics can change lives. Read More © Copyright Actorius Innovations and Research In the News Explore how Actorius is making headlines in cancer research and diagnostics. View all mentions 29 Aug 2026 'कॅन्सर'ची टेस्ट शोधणाऱ्या मराठी माणसाचं आकाशाएवढं कर्तृत्व बघाच ! | डॉ.जयंत खंदारे. धाराशिवच्या डॉ. जयंत खंदारे यांनी अमेरिकेत संशोधन करून रक्तावरून कॅन्सरचे निदान करणारी जगातील केवळ दुसरी टेस्ट विकसित केली आहे. पुणे आणि अमेरिकेत त्यांच्या लॅब असून, कॅन्सर जनजागृतीसह त्यांच्या या महत्त्वपूर्ण शोधाच्या प्रेरणादायी प्रवासाचा घेतलेला हा वेध. Read More 24 May 2026 The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. Read More 17 Mar 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More FAQS Frequently Asked Questions Answers to commonly asked questions about Actorius and our offerings. Know More What makes Actorius different from conventional diagnostics companies? Actorius focuses on understanding cancer at the cellular level and translating that insight into precise, actionable outcomes. Our platforms are designed to look deeper, act earlier, and support more confident decisions. Who are Actorius’ solutions designed for? Our solutions are built for clinicians, researchers, healthcare partners, and institutions seeking advanced tools for cancer detection, analysis, and monitoring. How does Actorius approach precision oncology? We combine advanced biomaterials, biological insight, and data-driven analysis to study cancer behavior in detail—enabling earlier detection and more targeted intervention. Are Actorius’ technologies research-only or clinically applicable? Our work spans both research and translational applications. Some solutions are designed for research use, while others are developed with clinical deployment in mind, subject to regulatory requirements. How can I stay updated on Actorius’ work and developments? You can explore our latest blogs, newsletters, press releases, case studies, and events in the Resources section to stay informed about our progress and insights. Early detection is half the battle won. Empowering earlier insights so decisions can be made with confidence and care. Know More

Comprehensive ctDNA and CTC profiling predicts metastasis in early breast cancer. Publications | 15 January 2023 AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. Background Genomic profiling has revolutionized precision oncology, impacting diagnosis, prognosis, and therapy decisions. Considering the high spatiotemporal diversity and heterogeneity of breast tumor-cell genomes, small-gene panels often fail to capture rare but important genomic alterations. Conversely, comprehensive ctDNA sequencing approaches enable the identification of under-characterized 'long-tailed driver' genomic alterations and capture intra- and inter-metastatic heterogeneity. Here, we demonstrate the clinical utility of comprehensive genome profiling with higher sensitivity to predict the possibility of metastasis in early-stage breast cancer patients. Methods We retrospectively analyzed ctDNA and genomic DNA (gDNA) from FFPE samples, as well as circulating tumor cells (CTCs), in 10 treatment-naive, hormone-positive, and HER2-negative primary-stage breast cancer patients using the OncoIndx comprehensive 600-gene panel. The panel captures all important cancer-relevant genomic alterations, including tumor mutation burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD) prediction, and cfDNA tumor fraction (TF). CTCs were enumerated from 1.5 ml of blood using the OncoDiscover platform, approved by the Drug Controller General of India, using anti-EpCAM antibody-mediated immunomagnetic nanoparticles. CTCs were confirmed for cytokeratin 18+ and DAPI+ markers, and the absence of CD45. Results The comprehensive genomic profile obtained from ctDNA and gDNA from the FFPE of early-stage breast cancer patients predominantly exhibited the presence of alterations in PIK3CA and ESR1 signaling pathways. PIK3CA mutations were present in 77% and 44% of baseline ctDNA and gDNA samples, while ESR1 mutations were present in 44% and 22% of baseline ctDNA and gDNA, respectively. In addition, we observed about 70% additional driver mutations in ctDNA samples, suggesting the shedding of ctDNA together with CTCs (80% positive) as a likely positive biomarker of metastasis. About 50% of the patients showed higher TMB and HRD. Notably, TF representing ctDNA varied between 13% to 27% in blood samples with a corresponding ploidy range of 2.9 to 4.7. Surprisingly, ~50% of the patient population matched the mutation profile of clinically confirmed metastatic patients. All the patients harboring potential metastatic driver alterations showed the presence of CTCs in peripheral blood. Conclusions Comprehensive ctDNA genomic profiling showed potential metastasis-driving alterations, suggesting the role of ctDNA-based liquid biopsy to predict metastasis in early breast cancer patients. We observed enhanced TF at the time of diagnosis, possibly due to the presence of distant metastasis, high disease burden, and aggressive tumor biology. Our results suggest that ctDNA dynamics at the time of disease presentation can predict early metastasis and may demonstrate the divergent response of tumor heterogeneity to treatment in early-stage breast cancer. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Making cancer detection more accessible and affordable to people Press Release | 24 August 2019 Startup Mantra: Making cancer detection more accessible and affordable to people Launching ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test which can be performed multiple times requiring 1.5ml blood volume... Actorius Innovations and Research Pvt. Ltd. Read full release Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Explore our innovative patents. Discover the power of innovation and precision in our groundbreaking patent solutions. Patents & Certifications Proof of Precision. Power of Innovation. We are committed to utmost scientific rigour. Every product at Actorius Innovations and Research undergoes intense design and development. Our products are patented worldwide. We follow the most stringent quality norms (ISO13485) and applicable regulatory requirements for medical devices (rules 2017) 20 Oct 2025 Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Read More 13 Feb 2023 Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Read More 22 Apr 2021 Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Read More 26 Feb 2020 Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Read More First Prev 1 Page 1 Next Last

Product Manager Publication Date: 26 Aug 2026 | Last Application Date: 6 Oct 2026 Apply Now Department Product & Marketing Location Mumbai, India Experience 3-5 years Role Overview The Product Manager will own the commercial and strategic lifecycle of Actorius products, working closely with scientific, clinical, sales and marketing teams to translate product capabilities into market-ready solutions. Key Responsibilities Develop and maintain product strategy and roadmap. Understand clinical, customer and market requirements. Work closely with scientific and technical teams to understand product capabilities. Translate technical and scientific information into customer-facing value propositions. Develop product positioning, messaging and sales enablement materials. Conduct market research and competitive analysis. Identify new market opportunities and customer segments. Support product launches and market-expansion initiatives. Work closely with Sales and Marketing teams on product adoption. Develop product presentations, FAQs, brochures, training materials and other collateral. Conduct product training for internal sales teams. Gather customer feedback and convert insights into product-development recommendations. Monitor product performance, market acceptance and competitive positioning. Support conferences, medical events and customer engagements. Ensure product communication remains scientifically accurate and compliant. Qualifications & Skills Bachelor's/Master's degree in Biotechnology, Life Sciences, Pharmacy, Medicine, Biomedical Sciences or a related field. MBA in Marketing/Product Management is an advantage. 3–5 years of product management experience , preferably in diagnostics, IVD, medical devices, pharma or biotechnology. Strong understanding of healthcare products and customer journeys. Ability to understand scientific literature and communicate technical information clearly. Excellent presentation, analytical and stakeholder-management skills. What We Look For At Actorius, we value people who combine ownership, curiosity, scientific thinking and execution . We look for professionals who are: Passionate about healthcare and meaningful innovation. Comfortable working in a fast-growing, innovation-driven environment. Curious and willing to learn. Strong in communication and collaboration. Focused on outcomes and accountability. Comfortable working across functions. Ethical and professional in their approach. Motivated by the opportunity to contribute to technologies that can impact cancer care. About Actorius Actorius Innovations & Research Pvt. Ltd. is an innovation-driven biotechnology and medical diagnostics company focused on developing technologies that address critical challenges in cancer care. From breakthrough research to clinically meaningful diagnostics, Actorius works at the intersection of biotechnology, biomaterials, circulating tumor cells (CTCs), liquid biopsy and oncology diagnostics . Our goal is to translate deep scientific understanding into practical technologies that can help clinicians make more informed decisions and improve patient outcomes. Our flagship OncoDiscover® CTC Test is India's first DCGI/CDSCO-approved blood test for detecting circulating tumor cells and supporting cancer monitoring. Actorius also continues to develop advanced technologies such as OncoMetastat® , alongside its broader research and diagnostic platforms. We are looking for dynamic thinkers, problem-solvers and doers who want to work on meaningful challenges in healthcare and contribute to technologies that can make a difference in cancer care. Why Join Actorius? Work on Meaningful Healthcare Challenges Contribute to technologies focused on cancer diagnostics, CTCs, liquid biopsy and oncology. Be Part of an Innovation-Driven Organisation Work alongside scientists, clinicians, business leaders and healthcare professionals. Learn Across Disciplines Actorius encourages interdisciplinary thinking across science, technology, diagnostics, marketing, sales and operations. Build With Purpose Our work is driven by the belief that better biological insights can contribute to better healthcare decisions. Grow With the Organisation Join a growing team where ownership, initiative and individual contribution matter. How to Apply Click the below link to apply. Candidates are encouraged to clearly mention the position and preferred location in their application. Apply Now

CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Publications | 4 April 2024 Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Background The lack of appropriate prognostic biomarkers remains a significant obstacle in the early detection of Head and Neck Squamous Cell Carcinoma (HNSCC), a cancer type with a high mortality rate. Despite considerable advancements in treatment, the success in diagnosing HNSCC at an early stage still needs to be improved. Nuclear factor erythroid 2-related factor 2 (Nrf2) and Sonic Hedgehog (Shh) are overexpressed in various cancers, including HNSCC, and have recently been proposed as possible therapeutic targets for HNSCC. Circulating Tumor Cell (CTC) is a novel concept used for the early detection of cancers, and studies have suggested that a higher CTC count is associated with the aggressiveness of HNSCC and poor survival rates. Therefore, we aimed to establish molecular markers for the early diagnosis of HNSCC considering Shh/Nrf2 overexpression in the background. In addition, the relation between Shh/Nrf2 and CTCs is still unexplored in HNSCC patients. Methods In the present study, we selected a cohort of 151 HNSCC patients and categorized them as CTC positive or negative based on the presence or absence of CTCs in their peripheral blood. Data on demographic and clinicopathological features with the survival of the patients were analyzed to select the patient cohort to study Shh/Nrf2 expression. Shh and Nrf2 expression was measured by qRT-PCR. Results Considering significant demographic [smoking, betel leaf (p-value < 0.0001)] and clinicopathological risk factors [RBC count (p < 0.05), Platelet count (p < 0.05), Neutrophil count (p < 0.005), MCV (p < 0.0001), NLR (p < 0.05), MLR (p < 0.05)], patients who tested positive for CTC also exhibited significant overexpression of Shh/Nrf2 in both blood and tissue compared to CTC-negative patients. A strong association exists between CTCs and tumor grade. Following chemotherapy (a combination of Cisplatin, 5FU, and Paclitaxel), the frequency of CTCs was significantly decreased in patients with HNSCC who had tested positive for CTCs. The Kaplan–Meier plot illustrated that a higher number of CTCs is associated with poorer overall survival (OS) in patients with HNSCC. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 profiling across cancers supports monitoring, recurrence detection, and MRD. Publications | 3 June 2025 Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Background India presents a diverse genetic pool with varying cancer incidence patterns. Common cancers in the Indian population include head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers. Understanding the distribution of circulating tumor cells (CTCs) across these cancers may help account for cellular minimal residual disease (MRD) and early recurrence in solid tumors. Surgery with curative intent can be further evaluated for residual disease using dual biomarkers such as ctDNA and CTCs. Methods In this retrospective analysis, peripheral blood samples from 5,935 patients across various cancer types—including head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers—were evaluated for the presence of CTCs, with and without PD-L1 overexpression and CTC clusters. CTCs were detected using the OncoDiscover platform approved by CDSCO in 1.5 mL of peripheral blood. The platform utilizes a multifunctional magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibodies. CTCs were confirmed as EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ cells. PD-L1 expression on CTCs was analyzed using linear fluorescence intensity gradients acquired through an automated Zeiss microscope. Additionally, a computational model was developed to evaluate CTC frequency, mean distribution, regression analysis, and normal probability plots to assess predictability across cancer types, age groups, stages, and genders. Results The study included 5,935 patient blood samples, comprising 90.07% baseline and 9.92% follow-up samples. CTC counts ranged from 1 to 10 per 1.5 mL of blood, with a mean value of 1.12. Among the patients, 69.87% (n = 2,854) demonstrated PD-L1 expression on their CTCs, with a mean value of 0.99. The 51–60-year age group exhibited the highest proportion of both total CTCs (19.16%, n = 1,137) and PD-L1–positive CTCs (19.71%, n = 805). Most CTC clusters were identified in breast, colorectal, and endometrial cancers. Pancreatic cancer patients showed the highest mean CTC count (1.4), whereas laryngeal cancer samples had the lowest mean count (0.78). The computational model indicated that the 51–60-year age group had the highest impact on cancer prevalence and mean CTC distribution. The model also demonstrated a strong correlation between blood-based outcomes and normal probability scores. Conclusions Higher CTC counts were strongly associated with advanced disease stages, particularly in cancers prone to hematogenous spread, such as breast, lung, and prostate cancers. Incorporating CTC profiling from baseline into diagnostic and surveillance strategies may enhance personalized cancer management. The presence of CTCs in disease-free survival (DFS) settings suggests potential links to poor therapeutic response, disease progression, and minimal residual disease. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius Innovations at ASCO 2026 Publications | 17 March 2026 ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Abstract Background Minimal cellular residual disease (MCRD) with PD-L1 expression on circulating tumor cells (CTCs) is highly evidenced for possible aggressive diseases systemically. CTCs captured using N-cadherin—a calcium-dependent transmembrane glycoprotein—targets epithelial-mesenchymal transition (EMT) tumor cells. There is a difference in phenotypic specificity, as EpCAM likely misses CTCs that have undergone EMT, while N-cadherin enables the detection of these aggressive, invasive cells. Thus, N-cadherin-based CTC capture is more effective for identifying metastasis-prone CTCs. Using both markers together may improve overall CTC capture efficiency to provide a more comprehensive landscape of tumor heterogeneity and disease progression. We show the comparative and paired outcome of CTC capture using both anti-EpCAM antibodies versus N-cadherin across solid cancers. Methods Retrospectively, we compared 33 patients with different stages of breast, rectal, colon, prostate, lung, and other cancers. CTCs were detected using an affinity marker-independent isolation platform to avoid EpCAM bias. CTCs were isolated using a marker-independent, anti-EpCAM-positive, and N-cadherin-positive OncoDiscover platform evaluating PD-L1+ expression using automated Zeiss microscopy. Anti-EpCAM-positive and N-cadherin-positive CTCs were classified using validated intensity thresholds, concordance/discordance rates, cluster frequency, and the mean distribution of CTCs. Results OncoDiscover platform EpCAM and N-cadherin expression showed an overall concordance of 60.61% and a discordance of 39.39%, indicating EMT-related phenotypic divergence. The mean CTC counts were comparable between anti-EpCAM-positive and N-cadherin-positive samples (0.66 and 0.70 per sample, respectively). Among EpCAM-positive CTCs, 42.85% expressed PD-L1, whereas PD-L1 positivity was lower and present in 30.30% of N-cadherin-positive CTCs. Importantly, 4 N-cadherin+/EpCAM- PD-L1-positive CTCs were identified, which were not captured by EpCAM affinity; conversely, 6 EpCAM+/PD-L1+ CTCs lacked N-cadherin expression. Notably, CTC clusters were found in 12.12% of EpCAM+ cases and 6.06% of N-cadherin-positive cases. Collectively, these findings demonstrate that dual-marker profiling improves detection sensitivity relative to single-marker interrogation. Conclusions Using both EpCAM and N-cadherin together improved CTC capture efficiency. However, N-cadherin-based CTC capture is more implicative in identifying metastasis-prone CTCs. The dual affinity accounts for CTCs for MCRD surveillance for the presence of disease systemically and is indicative of the progression of micro-metastasis. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Large study shows CTCs and clusters predict aggressive epithelial cancer progression. Publications | 10 April 2024 AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance. Background: The role of circulating tumor cells (CTCs) in metastatic cancers for predicting overall survival has been well established. The effectiveness of three- or six-month adjuvant therapy in colorectal cancer estimation has shown an association between CTCs and the emergence of resistant cell clones. The presence of CTC clusters indicates increased aggressiveness in epithelial cancers. However, the presence of CTC clusters has not been evaluated in large patient populations. Here, we demonstrate the distribution and prognostic significance of CTCs and CTC clusters in epithelial cancer patients. Methods: Retrospectively, blood samples from 3458 patients were analyzed for the presence and distribution of CTCs and CTC clusters using the DCGI-approved OncoDiscover platform, which uses an immunomagnetic multicomponent system mediated by an anti-EpCAM antibody. A total of 1.5 mL of peripheral blood was analyzed to capture cells and clusters from head and neck, breast, and lung cancer patients. The sensitivity, specificity, and accuracy of the OncoDiscover assay had been previously established. CTCs and clusters were identified using CK18 positive, DAPI positive, and CD45 negative staining with automated motorized fluorescence microscopy. CTC clusters were defined as the presence of two or more CTCs bound together. Results: Out of 3458 epithelial cancer patients, 65.52% (2262 patients) showed the presence of CTCs, with CTC numbers varying from 1–9 per 1.5 mL of blood. Meanwhile, 7.54% of patients showed CTC clusters, corresponding to 261 clusters. The total number of captured CTCs and clusters was 19,345, with a mean distribution of 5.59. Among these, CTCs accounted for 19,037 (98.41%), while clusters accounted for 308 (1.59%). The highest number of CTCs was observed in head and neck cancers (52.98%) and breast cancers (22.75%), followed by lung cancer (5.65%). In contrast, clusters were most frequently observed in breast cancers (26.95%), followed by lung cancer (16.23%). Conclusions: The frequency and distribution of CTCs and CTC clusters were evaluated in epithelial cancers. Patients with CTCs alone and those with both CTCs and CTC clusters represent a more aggressive disease state and a higher likelihood of disease progression. The effectiveness of adjuvant therapy in epithelial cancers may be estimated using CTC and cluster analysis, as their presence may indicate treatment resistance and the emergence of resistant cell clones. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe